Objective:A meta-analysis was used to systematically study the correlation between inflammatory response and diabetic nephropathy based on Shenqi Dihuang Decoction.Methods:The RCT literatures related to the efficacy a...Objective:A meta-analysis was used to systematically study the correlation between inflammatory response and diabetic nephropathy based on Shenqi Dihuang Decoction.Methods:The RCT literatures related to the efficacy and inflammatory response of Shenqi Dihuang Decoction in the treatment of diabetic nephropathy in Chinese and English databases were searched.The time limit was from the establishment of the database to February 2020.Literature screening and data extraction were performed according to the criteria for inclusion and exclusion.The evaluator's manual 5.1.0 was used to evaluate the risk of bias in the final included literature.Meta-analysis was performed using RevMan 5.3 software.Comparing western medicine treatment and Shenqi Dihuang decoction to inflammatory factors:interleukin-6(IL-6)Interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),C-reactiveprotein(CRP),intercellular adhesion molecule-1(MCP-1),and monocyte chemotactic protein-1(ICAM-1)and efficacy indicators:the impact of urine microalbumin(mALB)and clinical efficacy.Results:A total of 11 related research reports were finally included,of which 9 evaluated IL-6[SMD=-1.09,95%CI(-1.57,-0.61),Z=4.43,P<0.00001];5 Item evaluated IL-8[SMD=-0.91,95%CI(-1.44,-0.37),Z=3.33,P=0.0009<0.05];7 items evaluated TNF-[SMD=-0.97,95%CI(-1.49,-0.45),Z=3.63,P=0.0003<0.05];9 items evaluated CRP[SMD=-1.40,95%CI(-1.89,-0.90),Z=5.49,P<0.00001];2 items evaluated MCP-1[SMD=-0.71,95%CI(-1.00,-0.43),Z=4.95,P<0.00001];1 item was ICAM-1 Evaluation was performed[SMD=-0.98,95%CI(-1.38,-0.58),Z=4.82,P<0.00001];6 items used mALB as the efficacy index[SMD=-1.85,95%CI(-2.65,-1.05),Z=4.52,P<0.00001];9 items evaluated the clinical efficacy,[OR=4.45,95%CI(2.96,6.69),Z=7.17,P<0.00001].Conclusion:Shenqi Dihuang Decoction was used in patients with diabetic nephropathy.Compared with the western medicine treatment group,the levels of IL-6,IL-8,TNF-α,CRP,MCP-1,ICAM-1and inflammatory factors were significantly reduced.The effect is significantly increased.It is suggested that Shenqi Dihuang Decoction has better anti-inflammatory response than diabetic nephropathy than western medicine alone.展开更多
目的探讨参芪地黄汤化裁联合胰岛素治疗在二甲双胍控制血糖不佳气阴两虚证糖尿病患者中的应用价值。方法选取2019年3月—2022年6月就诊的100例二甲双胍控制血糖不佳气阴两虚证糖尿病开展回顾性研究,均为2型糖尿病。根据治疗方法不同分...目的探讨参芪地黄汤化裁联合胰岛素治疗在二甲双胍控制血糖不佳气阴两虚证糖尿病患者中的应用价值。方法选取2019年3月—2022年6月就诊的100例二甲双胍控制血糖不佳气阴两虚证糖尿病开展回顾性研究,均为2型糖尿病。根据治疗方法不同分为研究组和常规组,每组50例。研究组采用参芪地黄汤化裁联合胰岛素治疗,常规组采用胰岛素治疗。比较2组疗效、中医证候积分、血糖相关指标[糖化血红蛋白(HbA1c)、稳态模型胰岛素抵抗指数(HOMA-IR)、餐后2 h血糖(2 h PBG)、空腹血糖(FBG)、胰岛β细胞功能指数(HOMA-β)]、炎性指标[C反应蛋白(CRP)、单核细胞趋化蛋白-1(MCP-1)、白血病抑制因子(LIF)、高迁移率族蛋白B1(HMGB1)]、预后指标[脂蛋白相关磷脂酶A2(Lp-PLA2)、血尿酸(SUA)、甲状腺球蛋白(TG)]及安全性。结果研究组临床总有效率94.00%(47/50)高于常规组80.00%(40/50)(P<0.05)。治疗后研究组各中医证候积分及总积分低于常规组(P<0.05)。治疗后研究组HbA1c、2 h PBG、FBG、HOMA-IR低于常规组,HOMA-β高于常规组(P<0.05)。治疗后研究组CRP、MCP-1、LIF、HMGB1、Lp-PLA2、SUA、TG低于常规组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论参芪地黄汤化裁联合胰岛素治疗二甲双胍控制血糖不佳气阴两虚证糖尿病患者效果显著,可有效降低血糖水平,改善临床症状,减轻炎症反应,且安全性高。展开更多
目的观察参芪麦味地黄汤治疗气阴两虚型2型糖尿病的临床效果、安全性。方法选取气阴两虚型2型糖尿病患者70例,随机分为对照组和治疗组,各35例。对照组患者给予盐酸二甲双胍片进行治疗,治疗组患者给予盐酸二甲双胍片联合参芪麦味地黄汤...目的观察参芪麦味地黄汤治疗气阴两虚型2型糖尿病的临床效果、安全性。方法选取气阴两虚型2型糖尿病患者70例,随机分为对照组和治疗组,各35例。对照组患者给予盐酸二甲双胍片进行治疗,治疗组患者给予盐酸二甲双胍片联合参芪麦味地黄汤进行治疗,比较两组患者的治疗效果。结果治疗后,两组中医证候积分均下降,与治疗前比较差异有统计学意义(P<0.05),且治疗组优于对照组(P<0.05);治疗组患者的空腹血糖(FPG)水平、餐后2 h血糖水平(2 h PG)和糖化血红蛋白水平(HbA1c)明显降低,与对照组比较差异有统计学意义(P<0.05)。治疗组总有效率97.14%(34/35)高于对照组的71.43%(25/35),差异有统计学意义(P<0.05)。结论参芪麦味地黄汤可以明显改善气阴两虚型2型糖尿病患者的临床症状,能够有效降低患者的FPG水平、2 h PG水平和HbA1c水平,比单纯西药治疗效果更显著,值得临床辨证应用。展开更多
基金Research project of TCM of Jiangxi provincial health and family planning commission(No.2018A004)
文摘Objective:A meta-analysis was used to systematically study the correlation between inflammatory response and diabetic nephropathy based on Shenqi Dihuang Decoction.Methods:The RCT literatures related to the efficacy and inflammatory response of Shenqi Dihuang Decoction in the treatment of diabetic nephropathy in Chinese and English databases were searched.The time limit was from the establishment of the database to February 2020.Literature screening and data extraction were performed according to the criteria for inclusion and exclusion.The evaluator's manual 5.1.0 was used to evaluate the risk of bias in the final included literature.Meta-analysis was performed using RevMan 5.3 software.Comparing western medicine treatment and Shenqi Dihuang decoction to inflammatory factors:interleukin-6(IL-6)Interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),C-reactiveprotein(CRP),intercellular adhesion molecule-1(MCP-1),and monocyte chemotactic protein-1(ICAM-1)and efficacy indicators:the impact of urine microalbumin(mALB)and clinical efficacy.Results:A total of 11 related research reports were finally included,of which 9 evaluated IL-6[SMD=-1.09,95%CI(-1.57,-0.61),Z=4.43,P<0.00001];5 Item evaluated IL-8[SMD=-0.91,95%CI(-1.44,-0.37),Z=3.33,P=0.0009<0.05];7 items evaluated TNF-[SMD=-0.97,95%CI(-1.49,-0.45),Z=3.63,P=0.0003<0.05];9 items evaluated CRP[SMD=-1.40,95%CI(-1.89,-0.90),Z=5.49,P<0.00001];2 items evaluated MCP-1[SMD=-0.71,95%CI(-1.00,-0.43),Z=4.95,P<0.00001];1 item was ICAM-1 Evaluation was performed[SMD=-0.98,95%CI(-1.38,-0.58),Z=4.82,P<0.00001];6 items used mALB as the efficacy index[SMD=-1.85,95%CI(-2.65,-1.05),Z=4.52,P<0.00001];9 items evaluated the clinical efficacy,[OR=4.45,95%CI(2.96,6.69),Z=7.17,P<0.00001].Conclusion:Shenqi Dihuang Decoction was used in patients with diabetic nephropathy.Compared with the western medicine treatment group,the levels of IL-6,IL-8,TNF-α,CRP,MCP-1,ICAM-1and inflammatory factors were significantly reduced.The effect is significantly increased.It is suggested that Shenqi Dihuang Decoction has better anti-inflammatory response than diabetic nephropathy than western medicine alone.
文摘目的探讨参芪地黄汤化裁联合胰岛素治疗在二甲双胍控制血糖不佳气阴两虚证糖尿病患者中的应用价值。方法选取2019年3月—2022年6月就诊的100例二甲双胍控制血糖不佳气阴两虚证糖尿病开展回顾性研究,均为2型糖尿病。根据治疗方法不同分为研究组和常规组,每组50例。研究组采用参芪地黄汤化裁联合胰岛素治疗,常规组采用胰岛素治疗。比较2组疗效、中医证候积分、血糖相关指标[糖化血红蛋白(HbA1c)、稳态模型胰岛素抵抗指数(HOMA-IR)、餐后2 h血糖(2 h PBG)、空腹血糖(FBG)、胰岛β细胞功能指数(HOMA-β)]、炎性指标[C反应蛋白(CRP)、单核细胞趋化蛋白-1(MCP-1)、白血病抑制因子(LIF)、高迁移率族蛋白B1(HMGB1)]、预后指标[脂蛋白相关磷脂酶A2(Lp-PLA2)、血尿酸(SUA)、甲状腺球蛋白(TG)]及安全性。结果研究组临床总有效率94.00%(47/50)高于常规组80.00%(40/50)(P<0.05)。治疗后研究组各中医证候积分及总积分低于常规组(P<0.05)。治疗后研究组HbA1c、2 h PBG、FBG、HOMA-IR低于常规组,HOMA-β高于常规组(P<0.05)。治疗后研究组CRP、MCP-1、LIF、HMGB1、Lp-PLA2、SUA、TG低于常规组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论参芪地黄汤化裁联合胰岛素治疗二甲双胍控制血糖不佳气阴两虚证糖尿病患者效果显著,可有效降低血糖水平,改善临床症状,减轻炎症反应,且安全性高。
文摘目的观察参芪麦味地黄汤治疗气阴两虚型2型糖尿病的临床效果、安全性。方法选取气阴两虚型2型糖尿病患者70例,随机分为对照组和治疗组,各35例。对照组患者给予盐酸二甲双胍片进行治疗,治疗组患者给予盐酸二甲双胍片联合参芪麦味地黄汤进行治疗,比较两组患者的治疗效果。结果治疗后,两组中医证候积分均下降,与治疗前比较差异有统计学意义(P<0.05),且治疗组优于对照组(P<0.05);治疗组患者的空腹血糖(FPG)水平、餐后2 h血糖水平(2 h PG)和糖化血红蛋白水平(HbA1c)明显降低,与对照组比较差异有统计学意义(P<0.05)。治疗组总有效率97.14%(34/35)高于对照组的71.43%(25/35),差异有统计学意义(P<0.05)。结论参芪麦味地黄汤可以明显改善气阴两虚型2型糖尿病患者的临床症状,能够有效降低患者的FPG水平、2 h PG水平和HbA1c水平,比单纯西药治疗效果更显著,值得临床辨证应用。
